Please ensure Javascript is enabled for purposes of website accessibility

Monsanto Plowed Down

By Brian Orelli, PhD – Updated Apr 6, 2017 at 1:02AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Low end of guidance is better than lowered guidance, I guess.

There's nowhere to go but down.

Monsanto (NYSE:MON) knew that revenue from its herbicide, Roundup, would peak this year. Unfortunately, it peaked a little lower than expected.

The agriculture giant said that it expects to hit the low end of its earnings guidance this fiscal year because it'll only bring in $2 billion in gross profit from Roundup and other glyphosate products compared to the $2.4 billion it previously expected.

The lower revenue appears to be mostly due to strong competition from Syngenta (NYSE:SYT), Dow Chemical (NYSE:DOW), and Chinese generics, which has forced Monsanto to lower the price of its Roundup. That's good news for fertilizer producers like PotashCorp (NYSE:POT), Mosaic (NYSE:MOS), and Agrium (NYSE:AGU), because it means the lower sales aren't entirely due to external factors that are causing farmers to plant less acreage.

Higher sales of seeds should make up for some of the missing profit, but hitting $4.40 in earnings this year is still a disappointment -- especially for a company that seems to be constantly raising guidance.

While the short-term outlook for Monsanto might not look as rosy, the long-term future of Monsanto was never based on Roundup. As long as the company can continue to develop seeds that increase yields, and consequently profit for farmers, they'll be able to increase revenue and earnings. It's the seeds -- not the chemicals -- that are the future of Monsanto, and seed sales are headed in the right direction.

Trading at over 30 times expected free cash flow for this fiscal year, Monsanto certainly doesn't look insanely cheap. But high-growth companies hardly ever do.

Motley Fool Rule Breakers is always on the hunt for hot drug stocks and other cutting-edge picks. Click here to see all of our latest discoveries with a free 30-day trial subscription.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Monsanto Company Stock Quote
Monsanto Company
MON
Nutrien Stock Quote
Nutrien
POT
DuPont de Nemours, Inc. Stock Quote
DuPont de Nemours, Inc.
DOW
The Mosaic Company Stock Quote
The Mosaic Company
MOS
$48.53 (-7.60%) $-3.99

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.